VRP Verona Pharma Plc

 
TIDMVRP 
 
 
   LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces today that Piers Morgan, Chief 
Financial Officer of Verona Pharma, will present at BioEURquity Europe 
2018 to be held May 14-16, 2018 in Ghent, Belgium. 
 
   Piers Morgan, Chief Financial Officer is scheduled to present Tuesday, 
May 15(th)  at 5:20 PM CEST. For more information please visit 
www.veronapharma.com 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has shown clinically meaningful 
and statistically significant improvements in lung function and clinical 
symptoms as compared to placebo, and has shown statistically significant 
improvements in lung function when administered in addition to 
frequently used short- and long-acting bronchodilators as compared to 
such bronchodilators administered as a single agent. Verona Pharma is 
developing RPL554 for the treatment of chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF), and potentially asthma. 
 
 
 
 
 
For further information, please contact: 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison   SNELVeronaPharma@stifel.com 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: +44 (0)20 3727 1000 
Simon Conway / Natalie Garland-Collins             veronapharma@fticonsulting.com 
 
ICR, Inc. (US Media and Investor enquiries) 
James Heins                                        Tel: +1 203-682-8251 
                                                    James.Heins@icrinc.com 
Stephanie Carrington                               Tel. +1 646-277-1282 
                                                    Stephanie.Carrington@icrinc.com 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

May 04, 2018 08:30 ET (12:30 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024